ライフサイエンスコーパス: simian

1 Wild-type SIV infection in macaques leads to simian Acquired Immunodeficiency Syndrome (AIDS), which

2 Simian adenovirus (ChAdOx1) encoding a genetic immune en

3 vaccination with dual-antigen vectors, using simian adenovirus and modified vaccinia virus Ankara vec

4 2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spik

5 A simian adenovirus vector vaccine strategy is effective a

6 f genome identity with two recently isolated simian adenoviruses that contain cross-species genome re

7 V-B76, is identical to two recently reported simian AdV (SAdV) genomes isolated from chimpanzees and

8 l swarm and allowed to naturally progress to simian AIDS and potential SIV-associated encephalitis (S

9 Because these animals do not develop simian AIDS despite maintaining high viral loads, there

10 re a natural host of SIV that do not develop simian AIDS.

11 The main vector of simian and human malaria in this biome is the mosquito A

12 r ribosomes and associated mRNAs from human, simian and mice cellular extracts, but did not selective

13 d complex manual behaviors in most Old World simians and in the New World cebus monkey.

14 ivity, but less is known about the nature of simian antibodies.

15 ured mammalian cells, worms, flies, rodents, simians, apes, and even humans, all indicate declining a

16 iviruses (family Flaviviridae) and two novel simian arteriviruses (family Arteriviridae) in wild Afri

17 patterns of evolution differ markedly among simian arteriviruses and among host species.

18 Simian arteriviruses are a diverse clade of viruses infe

19 Simian arteriviruses are a diverse group of related viru

20 t in addition to SIV, simian pegiviruses and simian arteriviruses are widespread and prevalent among

21 Our results indicate that multiple divergent simian arteriviruses can cause SHF.

22 suggests that one of these virus types, the simian arteriviruses, may have the potential to jump bet

23 in global redistribution of PFV and macaque simian foamy virus (SFVmac) integration sites toward cen

24 Zoonotic simian foamy viruses (SFVs) establish persistent infecti

25 entally infected crab-eating macaques, while simian hemorrhagic fever virus (SHFV) causes lethal vira

26 es and then crab-eating macaques with either simian hemorrhagic fever virus (SHFV) or Kibale red colo

27 The nsp1beta of simian hemorrhagic fever virus (SHFV) was identified as

28 were previously reported for the arterivirus Simian hemorrhagic fever virus (SHFV).

29 t HCV sequences designed to allow entry into simian hepatocytes failed to induce viremia in tamarins

30 When infused into viremic simian HIV (SHIV)-infected rhesus macaques, there was a

31 provided 100% protection in macaques against simian HIV and was safe in a 14-day clinical trial in se

32 PTM MAIT cells responded to SIV/simian HIV infection by proliferating and upregulating a

33 erived from the full proteomes of 82 SIV and simian HIV isolates.

34 lls in serial samples from naive and SIV- or simian HIV-infected PTM.

35 In a simian-HIV chimeric virus AD8 (SHIVAD8) macaque model, C

36 hen administered by injection that prevented simian-HIV infection upon repeat intrarectal challenge i

37 cutive low-dose intravaginal challenges with simian-HIV strain SF162P3, with more animals infected co

38 (and may have increased susceptibility to a simian-HIV vaginal challenge), while the microbicide red

39 ct of stem cell transplantation in a macaque simian/HIV (SHIV) system.

40 Thus, we studied 4 simian/HIV-infected, ART-suppressed rhesus macaques infu

41 sed a macaque model of repeated exposures to simian human immunodeficiency virus (SHIV) to investigat

42 can be induced by administration of N-803 to simian-human chimeric immunodeficiency virus-infected, A

43 The simian-human differences in proportional frontal tract v

44 tection against repeated penile exposures to simian-human immunodeficiency virus (SHIV(SF162P3)).

45 s) infected with a transmitted/founder (T/F) simian-human immunodeficiency virus (SHIV) (SHIV.C.CH505

46 a primary HIV-1 isolate (HIV-1JR-FL), and a simian-human immunodeficiency virus (SHIV) adapted for p

47 ally after priming with CD40L-adjuvanted DNA/simian-human immunodeficiency virus (SHIV) and boosting

48 ability to protect against a low-dose rectal simian-human immunodeficiency virus (SHIV) challenge.

49 pentavalent-vaccine-immunized macaques from simian-human immunodeficiency virus (SHIV) challenge.

50 s (bNAbs) can protect rhesus monkeys against simian-human immunodeficiency virus (SHIV) challenge.

51 es from hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge.

52 Ab-mediated (BnAb-mediated) protection from simian-human immunodeficiency virus (SHIV) challenge.

53 ed four barcoded stocks from subtype B and C simian-human immunodeficiency virus (SHIV) clones.

54 erapy given 24 h after oral exposure cleared simian-human immunodeficiency virus (SHIV) in a macaque

55 oughout the oral mucosae, the effects of HIV/simian-human immunodeficiency virus (SHIV) in these tiss

56 Simian-human immunodeficiency virus (SHIV) infection in

57 Vh-LS-F potently inhibited in vivo HIV-1 and simian-human immunodeficiency virus (SHIV) infection in

58 Simian-human immunodeficiency virus (SHIV) infection of

59 t non-human primates (NHPs) against chimeric simian-human immunodeficiency virus (SHIV) infection.

60 e C Env-specific CTLs in a macaque subtype B simian-human immunodeficiency virus (SHIV) model to dete

61 lly tested in robust cell-associated macaque simian-human immunodeficiency virus (SHIV) models with n

62 as they incompletely neutralize the clade C simian-human immunodeficiency virus (SHIV) stock (SHIV-3

63 We developed the following three new simian-human immunodeficiency virus (SHIV) stocks: SHIV-

64 unized animals were challenged rectally with simian-human immunodeficiency virus (SHIV) strain SF162P

65 We used a novel penile simian-human immunodeficiency virus (SHIV) transmission

66 imary isolates in vitro and protects against simian-human immunodeficiency virus (SHIV) when delivere

67 h reduced infection rates in studies of HIV, simian-human immunodeficiency virus (SHIV), and simian i

68 ylaxis in macaques chronically infected with simian-human immunodeficiency virus (SHIV), intriguingly

69 m 16 simian immunodeficiency virus (SIV)- or simian-human immunodeficiency virus (SHIV)-infected and

70 immunodeficiency virus (SIV)-infected NHPs, simian-human immunodeficiency virus (SHIV)-infected NHPs

71 between neutralizing antibodies elicited by simian-human immunodeficiency virus (SHIV)-infected rhes

72 humanized mice and one pivotal experiment in simian-human immunodeficiency virus (SHIV)-infected rhes

73 A robust simian-human immunodeficiency virus (SHIV)-macaque model

74 ed V3-glycan antibody PGT121, in chronically simian-human immunodeficiency virus (SHIV)-SF162P3-infec

75 e of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV).

76 ave shown that simian immunodeficiency virus/simian-human immunodeficiency virus (SIV/SHIV) exposure

77 y.IMPORTANCE In this study, we constructed a simian-human immunodeficiency virus carrying an R5 Kenya

78 sus macaques were inoculated orally with the simian-human immunodeficiency virus SHIVSF162P3.

79 of the ICs targeted with 7B2 in mice and in simian-human immunodeficiency virus-infected macaques.

80 Here, we infected rhesus macaques with simian-human immunodeficiency viruses (SHIV) and followe

81 cell loss in vivo, we infected macaques with simian-human immunodeficiency viruses (SHIV) and followe

82 Most simian-human immunodeficiency viruses (SHIVs) bearing en

83 V model of HIV-1 latency and cure.IMPORTANCE Simian-human immunodeficiency viruses (SHIVs) have been

84 Simian-human immunodeficiency viruses (SHIVs) have been

85 erred complete immunity against a mixture of simian-human immunodeficiency viruses (SHIVs) in nonhuma

86 ry HIV-1 envelope proteins-when expressed by simian-human immunodeficiency viruses in rhesus macaques

87 coded" challenge viruses and next-generation simian-human immunodeficiency viruses that may advance t

88 ntagonism of tetherin by Nef is a barrier to simian-human transmission of non-human primate lentiviru

89 nst a single high-dose challenge with HIV or simian/human (SIV/HIV) chimaeric viruses (SHIVs) respect

90 infant rhesus macaques orally infected with simian/human immunodeficiency virus (SHIV) (SHIV.C.CH505

91 of TAF and emtricitabine (FTC) could prevent simian/human immunodeficiency virus (SHIV) infection in

92 t early administration of bNAbs in a macaque simian/human immunodeficiency virus (SHIV) model is asso

93 Macaques were exposed to simian/human immunodeficiency virus (SHIV) vaginally eac

94 nterruption data from macaques infected with simian/human immunodeficiency virus (SHIV), we observe a

95 macaque model of intrarectal challenge with simian/human immunodeficiency virus (SHIV).

96 s macaques (RMs) (n = 13) were infected with simian/human immunodeficiency virus SHIV.C.CH505.375H.dC

97 T cells in the rhesus macaque (RM) model of simian immunodeficiency (SIV) infection.

98 bs) against HIV-1 that protect macaques from simian immunodeficiency HIV chimeric virus (SHIV).

99 s that were molecularly engineered with anti-simian immunodeficiency virus (anti-SIV) activity into r

100 d rhesus macaques infected with the human or simian immunodeficiency virus (HIV or SIV), respectively

101 virus (CMV) and human immunodeficiency/virus simian immunodeficiency virus (HIV/SIV) infections.

102 ence of a distinct subpopulation of human or simian immunodeficiency virus (HIV/SIV) sequences within

103 eta(+) T cells to control of live-attenuated simian immunodeficiency virus (LASIV) replication during

104 cytomegalovirus (RhCMV) strain 68-1-vectored simian immunodeficiency virus (RhCMV/SIV) vaccines are a

105 However, with the exception of simian immunodeficiency virus (SIV) (family Retroviridae

106 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) acquisition in human

107 Macrophages (M ) are infected by HIV/simian immunodeficiency virus (SIV) and are likely to ca

108 ine-induced antibodies to capture infectious simian immunodeficiency virus (SIV) and explored the rel

109 We found here that an ALVAC-simian immunodeficiency virus (SIV) and gp120 alum (ALVA

110 cent structures of lentiviral intasomes from simian immunodeficiency virus (SIV) and HIV have clarifi

111 Simian immunodeficiency virus (SIV) and human immunodefi

112 ata from macaques infected with a mixture of simian immunodeficiency virus (SIV) and simian-human imm

113 Natural hosts of simian immunodeficiency virus (SIV) avoid AIDS despite l

114 ations of male rhesus macaques infected with simian immunodeficiency virus (SIV) but not in uninfecte

115 nodes from pigtailed macaques infected with simian immunodeficiency virus (SIV) carrying HIV-1 rever

116 work and have been tested extensively in the simian immunodeficiency virus (SIV) challenge macaque mo

117 e route on protection against a heterologous simian immunodeficiency virus (SIV) challenge.

118 or remain unvaccinated and then undergo oral simian immunodeficiency virus (SIV) challenges 3 weeks l

119 caques infected with an attenuated strain of simian immunodeficiency virus (SIV) containing a stop co

120 The Nef accessory protein of simian immunodeficiency virus (SIV) engages the clathrin

121 y or hydrophobic residues typically found in simian immunodeficiency virus (SIV) Env to improve rhesu

122 mmunization, or the capacity to neutralize a simian immunodeficiency virus (SIV) Env-expressing pseud

123 human immunodeficiency virus type 1 (HIV-1)/simian immunodeficiency virus (SIV) envelope spike (Env)

124 nt study, we found that protection following simian immunodeficiency virus (SIV) exposure correlated

125 TANCE Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) express a small prot

126 lymorphism limits and complicates the use of simian immunodeficiency virus (SIV) for evaluation of hu

127 MVA-B13R expressing simian immunodeficiency virus (SIV) Gag and Pol and HIV

128 ycobacterium tuberculosis strains expressing simian immunodeficiency virus (SIV) genes safely induces

129 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) gp120 exterior envel

130 ons.IMPORTANCE Rhesus macaque infection with simian immunodeficiency virus (SIV) has served as an imp

131 ts of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) have been described

132 -1)-infected humans, African-origin, natural simian immunodeficiency virus (SIV) hosts, such as Afric

133 re we employed a barcoded synthetic swarm of simian immunodeficiency virus (SIV) in rhesus macaques t

134 erapy, showed consistent, durable control of simian immunodeficiency virus (SIV) in rhesus macaques.

135 to which these populations were infected by simian immunodeficiency virus (SIV) in vivo, to determin

136 GI) tract of Asian macaques with progressive simian immunodeficiency virus (SIV) infection and humans

137 s (RMs) vaccinated with Vif and Nef acquired simian immunodeficiency virus (SIV) infection at a lower

138 n genes that show a response to experimental simian immunodeficiency virus (SIV) infection in vervet

139 AIDS caused by simian immunodeficiency virus (SIV) infection is associa

140 Using the simian immunodeficiency virus (SIV) infection model, we

141 re we studied progressive and nonprogressive simian immunodeficiency virus (SIV) infection models in

142 ly regarded as the main source of latent HIV/simian immunodeficiency virus (SIV) infection of adult h

143 age proliferation occurs in the brain during simian immunodeficiency virus (SIV) infection of adult m

144 Studies of natural, nonpathogenic simian immunodeficiency virus (SIV) infection of African

145 Alternative model systems based on simian immunodeficiency virus (SIV) infection of macaque

146 Simian immunodeficiency virus (SIV) infection of rhesus

147 enesis of human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) infection, and block

148 BM-derived CD4(+) T cells, their fate during simian immunodeficiency virus (SIV) infection, and their

149 n pathways involved in establishing systemic simian immunodeficiency virus (SIV) infection, we necrop

150 mation and gut immune dysfunction during the simian immunodeficiency virus (SIV) infection.

151 lls (ILCs) located in the colon secondary to simian immunodeficiency virus (SIV) infection.

152 ) T cells in rhesus macaques with or without Simian immunodeficiency virus (SIV) infection.

153 fitting the model to experimental data from simian immunodeficiency virus (SIV) infections in contro

154 Experimental simian immunodeficiency virus (SIV) infections of nonhum

155 Currently available simian immunodeficiency virus (SIV) infectious molecular

156 A subtype C isolate was similar, while a simian immunodeficiency virus (SIV) isolate showed signi

157 n activity prevalent among diverse HIV-1 and simian immunodeficiency virus (SIV) isolates.

158 or of apoptosis (IAP), AZD5582, reverses HIV/simian immunodeficiency virus (SIV) latency.

159 different human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) lentiviruses.

160 diated in part by CD4 T cells.IMPORTANCE The simian immunodeficiency virus (SIV) macaque model repres

161 Comparative analysis of HIV and simian immunodeficiency virus (SIV) Nef proteins in the

162 Brain injury occurs within days in simian immunodeficiency virus (SIV) or human immunodefic

163 Our approach was to deliver the entire simian immunodeficiency virus (SIV) proteome by serial v

164 ) lymphocyte-depleted macaques infected with simian immunodeficiency virus (SIV) provide an increasin

165 adenovirus type 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinants and boo

166 is of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) reflects a balance b

167 Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) replication in human

168 The simian immunodeficiency virus (SIV) rhesus macaque model

169 oding the well-characterized molecular clone simian immunodeficiency virus (SIV) SIVmac239, resulting

170 d in all primate lentiviruses, and its HIV-2/simian immunodeficiency virus (SIV) SIVsm paralogue Vpx,

171 fected with Mycobacterium tuberculosis (Mtb)/simian immunodeficiency virus (SIV) suggests that cytopa

172 HIV and simian immunodeficiency virus (SIV) target CD4(+) T cell

173 abeys (SM) are well-studied natural hosts of simian immunodeficiency virus (SIV) that do not progress

174 olgus macaques (CMs) infected with wild-type Simian Immunodeficiency Virus (SIV) to those of CMs infe

175 ted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency virus (SIV) vaccine enhances pro

176 lls in GC B cell responses following various simian immunodeficiency virus (SIV) vaccine regimens in

177 Working with the macaque simian immunodeficiency virus (SIV) vaginal challenge mo

178 20 of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) was investigated for

179 We report here, in simian immunodeficiency virus (SIV)+ rhesus macaques and

180 (HIV) emergence following human exposures to simian immunodeficiency virus (SIV), an understanding of

181 sory proteins of primate lentiviruses HIV-1, simian immunodeficiency virus (SIV), and BIV all form ub

182 viruses-feline immunodeficiency virus (FIV), simian immunodeficiency virus (SIV), and human immunodef

183 sum A1 partially inhibited HIV-1, as well as simian immunodeficiency virus (SIV), murine leukemia vir

184 nhuman primates were coinfected with Mtb and simian immunodeficiency virus (SIV), recapitulating huma

185 ector to immunize monkeys with antigens from simian immunodeficiency virus (SIV), the macaque model f

186 orescence microscopy thoracic aortas from 16 simian immunodeficiency virus (SIV)- or simian-human imm

187 ere validated in archival brain tissues from Simian Immunodeficiency Virus (SIV)-infected and uninfec

188 he rhesus macaque AIDS virus model, infusing simian immunodeficiency virus (SIV)-infected animals wit

189 ts were detectable, but increased 20-fold in simian immunodeficiency virus (SIV)-infected animals.

190 In simian immunodeficiency virus (SIV)-infected Asian macaq

191 iciency virus (HIV)-infected individuals and simian immunodeficiency virus (SIV)-infected Asian macaq

192 fected monocytes and macrophages to HIV- and simian immunodeficiency virus (SIV)-infected cells in vi

193 ibe viral genomes persisting in ART-treated, simian immunodeficiency virus (SIV)-infected NHPs, simia

194 CV) in a naturally occurring lymphoma from a simian immunodeficiency virus (SIV)-infected rhesus maca

195 In a previous study, we found that in simian immunodeficiency virus (SIV)-infected rhesus maca

196 Antiretroviral-treated, chronically simian immunodeficiency virus (SIV)-infected rhesus maca

197 body-mediated CD8(+) lymphocyte depletion in simian immunodeficiency virus (SIV)-infected rhesus maca

198 Simian immunodeficiency virus (SIV)-infected sooty manga

199 Using simian immunodeficiency virus (SIV)-infected, long-term

200 duced probiotic Lactobacillus plantarum into Simian immunodeficiency virus (SIV)-inflamed intestinal

201 Using the simian immunodeficiency virus (SIV)-macaque model, we te

202 Here, we show a population of simian immunodeficiency virus (SIV)-specific CD8 T cells

203 Human immunodeficiency virus (HIV)- and simian immunodeficiency virus (SIV)-specific CD8(+) T ce

204 esponses are necessary for immune control of simian immunodeficiency virus (SIV).

205 t they are not natural hosts of HIV-1 or any simian immunodeficiency virus (SIV).

206 tion of Env defines pathogenic properties of simian immunodeficiency virus (SIV).

207 ants in inducing protective immunity against simian immunodeficiency virus (SIV).

208 monkeys (AGMs) are natural primate hosts of simian immunodeficiency virus (SIV).

209 ian-human immunodeficiency virus (SHIV), and simian immunodeficiency virus (SIV).

210 on by human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV).

211 ocytes in ART-treated macaques infected with simian immunodeficiency virus (SIV).

212 ssion, we performed a comprehensive study of simian immunodeficiency virus (SIV)/SHIV-infected infant

213 an green monkeys (AGMs) are natural hosts of simian immunodeficiency virus (SIVAGM).

214 man primates (NHPs) coinfected with a mutant simian immunodeficiency virus (SIVDeltaGY) that does not

215 re targeted by primate lentiviruses (HIV and simian immunodeficiency virus [SIV]) are of intense inte

216 nated monkeys to clear a subsequent virulent simian immunodeficiency virus challenge.

217 y reactivation of latent infection following simian immunodeficiency virus coinfection.

218 enhanced by substituting naturally occurring simian immunodeficiency virus Env residues at position 3

219 ollowing the cross-species transmission of a simian immunodeficiency virus from chimpanzees (SIVcpz)

220 the result of cross-species transmission of simian immunodeficiency virus from chimpanzees (SIVcpz).

221 Despite acute simian immunodeficiency virus infection, all animals rem

222 agrees well with the experimental data from simian immunodeficiency virus infections in morphine-add

223 odeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus isolate it has been tested

224 e of the Vif substrate receptor complex from simian immunodeficiency virus isolated from red-capped m

225 ctious molecular clones from two widely used simian immunodeficiency virus lineages (SIVmac251 and SI

226 viremia after infection with the pathogenic simian immunodeficiency virus mac239 (SIVmac239) clone.

227 Here, we used the rhesus macaque simian immunodeficiency virus model with and without ant

228 l reservoir during infections with HIV-1 and simian immunodeficiency virus of macaques (SIVmac).

229 degradation and inhibited wild-type SIVmac (simian immunodeficiency virus of macaques) infection of

230 iral protein X (Vpx) proteins from the major simian immunodeficiency virus of rhesus macaque, sooty m

231 Using the rhesus macaque simian immunodeficiency virus SIVmac251 model, we can co

232 ng a function of a cellular chaperone, since simian immunodeficiency virus T antigen was previously s

233 ed and published a description of a barcoded simian immunodeficiency virus that has a short random se

234 wing treatment, animals were coinfected with simian immunodeficiency virus to assess reactivation of

235 NK cell activity in cells infected with HIV, simian immunodeficiency virus, and other persistent viru

236 ue lungs by DeltasigH was not reactivated by simian immunodeficiency virus, despite high viral levels

237 Nef alleles from divergent clades of HIV and simian immunodeficiency virus, including from primary pa

238 We used Mycobacterium tuberculosis/simian immunodeficiency virus-coinfected (M. tuberculosi

239 ctivation in the context of ART using TB and simian immunodeficiency virus-coinfected (TB/SIV-coinfec

240 V) infection and colocalize in the aortas of simian immunodeficiency virus-infected nonhuman primates

241 Notably, evaluation of simian immunodeficiency virus-infected nonhuman primates

242 emia in antiretroviral therapy (ART)-treated simian immunodeficiency virus-infected rhesus macaques (

243 , some of which may be linked to response to simian immunodeficiency virus.

244 emained at protective levels despite chronic simian immunodeficiency virus/HIV-induced immunosuppress

245 ugh nonhuman primate studies have shown that simian immunodeficiency virus/simian-human immunodeficie

246 ally inhibit lentiviruses, such as human and simian immunodeficiency viruses (HIV and SIV), irrespect

247 Human and simian immunodeficiency viruses (HIV/SIVs) use CD4 as th

248 protein encoded by HIV-1 as well as by some simian immunodeficiency viruses (SIVs) infecting wild ch

249 Simian immunodeficiency viruses (SIVs) use their Nef pro

250 en widely accepted to be the consequences of simian immunodeficiency viruses from wild chimpanzees (S

251 h Nef is the viral gene product used by most simian immunodeficiency viruses to overcome restriction

252 Here, we used human and simian models to assess the impact of INSTIs on adipose

253 played an essential role in the evolution of simian neurotransmitter metabolism.

254 ery.IMPORTANCE Brain injury induced by acute simian (or human) immunodeficiency virus infection may p

255 discovery and characterization of two novel simian pegiviruses (family Flaviviridae) and two novel s

256 overies demonstrate that in addition to SIV, simian pegiviruses and simian arteriviruses are widespre

257 cells distinguishes HIV-1 Nef and its direct simian precursors from other primate lentiviruses.

258 First, we discovered that all simian primate genomes retain the remnants of an ancient

259 Temperature-sensitive (ts) mutants of simian rotavirus (RV) strain SA11 have been previously c

260 The simian RRV strain, but not murine EW RV, uniquely trigge

261 a tractable RG system for the rescue of the simian RRV strain, the human CDC-9 strain, and a murine-

262 Previously, a mutant simian RV (SA11-tsC) that replicates worse at higher tem

263 his RG system, we successfully recovered the simian RV RRV strain, the human RV CDC-9 strain, a reass

264 in, a reassortant between murine RV D6/2 and simian RV SA11 strains, and several reassortants and rep

265 correlate with restricted reassortment into simian RV strain SA11.

266 ses 11 T7 plasmids, each expressing a unique simian SA11 (+)RNA, and a cytomegalovirus support plasmi

267 icance of the B cell dysfunction observed in simian (SIV) and human immunodeficiency virus (HIV) infe

268 he immunodeficiency viruses, human (HIV) and simian (SIV); however, virus rebounds soon after ART is

269 Baboons naturally infected with simian T lymphotropic virus (STLV) are a potentially use

270 re we provide fundamental information on the simian T lymphotropic virus (STLV) naturally transmitted

271 ype D strain that was closely related to the simian T lymphotropic virus (STLV-1) that infects this m

272 he CD8(+) and CD4(+) T cell response against simian T-lymphotropic virus type 1 (STLV-1), a virus clo

273 on, we reconstituted the AP-2 complex with a simian tetherin and SIV Nef and determined its structure

274 lect an individual IMC, named stHIV-A19 (for simian tropic HIV-1 clone A19), which recapitulated the

275 e gene encoding a full-length protein in all simians under purifying selection and with similar shedd

276 ronchial inoculation of rhesus macaques with simian varicella virus (SVV) recapitulates the hallmarks

277 Infection of rhesus macaques with simian varicella virus (SVV), a homolog of VZV, provides

278 us macaques intrabronchially inoculated with simian varicella virus (SVV), the counterpart of human v

279 nchially challenged with the closely related Simian Varicella Virus (SVV).

280 eplicated efficiently and remained stable in simian Vero cells, which do not express these miRNAs, ho

281 an wild-type virus in human Caco-2 cells and simian Vero cells.

282 lian epithelial cell lines (human Calu-3 and simian Vero E6), we found that both IFNs dose-dependentl

283 Host range (HR) mutants of simian virus 40 (SV40) containing mutations in the C ter

284 teins essential for MYC ESE activity but not simian virus 40 (SV40) enhancer.

285 Simian virus 40 (SV40) exists as chromatin throughout it

286 The nonenveloped polyomavirus simian virus 40 (SV40) must penetrate the host endoplasm

287 M also suppressed the constitutively active simian virus 40 (SV40) promoter and globally decreased c

288 her defined oncogenic alleles, including the simian virus 40 (SV40) T antigen (TAg) and oncogenic H-R

289 re cultured in cell lines immortalized using simian virus 40 (SV40) T antigen, suggesting the possibi

290 d population of glial cells transformed with simian virus 40 (SV40) T antigen.

291 However, infectivity of the polyomavirus simian virus 40 (SV40) was not affected by CME-specific

292 In the case of the nonenveloped polyomavirus simian virus 40 (SV40), the virus penetrates the endopla

293 s is particularly important for viruses like simian virus 40 (SV40), which exist as chromatin through

294 overexpressed in several cancers and in the simian virus 40 (SV40)-transformed human fibroblast mode

295 oma cell line, in comparison to well-studied simian virus 40 and a number of other viruses.

296 is study, we modified the ABCA4 plasmid with simian virus 40 enhancer (SV40, pRHO-ABCA4-SV40) for enh

297 telomerase catalytic subunit (hTERT) and the simian virus 40 large-tumour antigen (SV40).

298 a luciferase reporter vector containing the simian virus 40 promoter.

299 emistry for cytomegalovirus, adenovirus, and simian virus 40 were negative.

300 interactions of a whole nonenveloped virus (simian virus 40), as well as those of the hepatitis delt